Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

Abstract Background Crenezumab, a fully humanized anti-beta-amyloid (Aβ) immunoglobulin G4 (IgG4) monoclonal antibody, binds to both monomeric and aggregated forms of Aβ. We assessed the pharmacokinetics (PK)/pharmacodynamics (PD) of crenezumab and its interaction with monomeric Aβ(1–40) and Aβ(1–42...

Full description

Bibliographic Details
Main Authors: Kenta Yoshida, Anita Moein, Tobias Bittner, Susanne Ostrowitzki, Helen Lin, Lee Honigberg, Jin Y. Jin, Angelica Quartino
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Alzheimer’s Research & Therapy
Subjects:
Pharmacokinetics
PK/PD
Plasma beta-amyloid
Nonlinear mixed-effects modeling
Target-mediated drug disposition model
Online Access:https://doi.org/10.1186/s13195-020-0580-2

Internet

https://doi.org/10.1186/s13195-020-0580-2

Similar Items